KR890000109A - 세포막의 안정화 방법 및 세포 표면 항원보호를 위한 이의 적용 - Google Patents
세포막의 안정화 방법 및 세포 표면 항원보호를 위한 이의 적용 Download PDFInfo
- Publication number
- KR890000109A KR890000109A KR1019880007700A KR880007700A KR890000109A KR 890000109 A KR890000109 A KR 890000109A KR 1019880007700 A KR1019880007700 A KR 1019880007700A KR 880007700 A KR880007700 A KR 880007700A KR 890000109 A KR890000109 A KR 890000109A
- Authority
- KR
- South Korea
- Prior art keywords
- membrane
- cell
- cells
- functional group
- cell membrane
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 15
- 210000000170 cell membrane Anatomy 0.000 title claims 6
- 101710160107 Outer membrane protein A Proteins 0.000 title 1
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 11
- 239000012528 membrane Substances 0.000 claims 10
- 125000000524 functional group Chemical group 0.000 claims 7
- 239000003381 stabilizer Substances 0.000 claims 4
- 230000000890 antigenic effect Effects 0.000 claims 3
- 230000004071 biological effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 150000003923 2,5-pyrrolediones Chemical class 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- 150000001409 amidines Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 150000001718 carbodiimides Chemical class 0.000 claims 1
- 125000003636 chemical group Chemical group 0.000 claims 1
- 150000001913 cyanates Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 150000002338 glycosides Chemical class 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002463 imidates Chemical class 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004999 nitroaryl group Chemical group 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
도면은 적혈구의 잔여 삼투압 파괴성을 나타낸다.
Claims (17)
- 적어도 이작용성이며 막을 단단하게 할 수 있는 안정화제(이 안정화제는 세포막의 생물학적 및 항원적 특성을 보존한 세포막이 회복될 수 있는 조건하에서 전위(dislocation) 또는 제거 가능하다)로 막을 처리함을 특징으로 하여, 표면 항원의 특성을 보호하는 형태로 세포, 막 또는 스트로마를 보존하기 위해 세포막을 안정화시키는 방법.
- 제 1 항에 있어서, 안정화제가 타입 F1-X-F2(여기에서 F1및 F2는 동일하거나 상이하며, 막 및/또는 세포의 단백질 또는 당염과, 또는 단백질의 작용기-NH2또는 -SH와 반응할 수 있는 화학적 그룹중에서 선태되고, X는 절단가능하지 않은 작용기 또는 결합으로 이루어진 작용기 또는 라디칼이다)인 방법.
- 제 2 항에 있어서, F1및 F2가 이미도에스테르, N-하이드록시-석신이미드 에스테르, 니트로아릴 할로게나이드, 카보디이미드, 시아네이트, 알데하이드, 말레이미드, 티오프탈이미드, 피리딜디설파이드, 활성할로겐, 전구체 니트렌 또는 카벤으로 이루어진 그룹으로부터 선택되는 방법.
- 제 2 항 또는 3항에 있어서, X가 세포막의 생물학적 및 항원적 특성을 보존한 세포막이 회복될 수 있는 조건하에서 절단 가능한 작용기 또는 결합을 함유하는 라디칼인 방법.
- 제 2 항 또는 3항에 있어서, X가 작용기이거나 eh는 포스페이트, 폴리팹티드, 에스테르, 아미딘, 디설파이드 및 작용기-N=N 또는 로 이루어진 그룹으로부터 선택된 작용기를 포함하는 방법.
- 제 2 항에 있어서, 제제 F1-X-F2가, 화합물 F1-R1및/ 또는 F2-R3를 일반식 R2-X-R4또는 R2-X-R2(여기에서, R1과 R2, 및 R3와 R4는 반응하여 결합을 형성할 수 있는 작용기이다)와 반응시킴으로써 동일반응게내에서 제조되는 방법.
- 제 1 항, 2항 또는 6항중 어느 한 항에 있어서, 안정화제를 그가 결합되어 있는 막 부위상에서 절단함으로써 제거할 수 있는 방법.
- 제 7 항에 있어서, 안정화제를 프로테아제에 의해 제거할 수 있는 방법.
- 제 1 항 내지 8항중 어느 한 항에 있어서, 세포가 혈액 및/ 또는 조혈 기관으로부터 유도된 세포인 방법.
- 제 9 항에 있어서, 세포가 적혈구, 그이 스트로마 또는 그의 막인 방법.
- 제 9 항에 있어서, 세포가 임파구인 방법.
- 제 9 항에 있어서, 세포가 과립구인 방법.
- 제 9 항에 있어서, 세포가 혈소판인 방법.
- 제 1 항 내지 13항 중 어느 한 항에 있어서, 세포, 스트로마, 또는 막이 치료적 및/ 또는 항원적 효능을 갖는 방법.
- 세포, 그의 스트로마 또는 막을 동결시키는데 있어서, 제 1 항 내지 14항중 어느 한 항에 따른 방법의 용도.
- 세포, 그의 스트로마 또는 막을 동결-건조시키는데 있어서, 제 1 항 내지 15항중 어느 한 항에 따른 방법의 용도.
- 세포, 스트로마 또는 막을 보존하는데 있어서, 제 1 항 내지 16항중 어느 한 항에 따른 방법의용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8708964A FR2617185B1 (fr) | 1987-06-25 | 1987-06-25 | Procede de stabilisation de membranes cellulaires et son app lication a la conservation des cellules sous une forme protegeant l'essentiel de leurs antigenes de surface |
| FR8708964 | 1987-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR890000109A true KR890000109A (ko) | 1989-03-11 |
Family
ID=9352508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019880007700A KR890000109A (ko) | 1987-06-25 | 1988-06-25 | 세포막의 안정화 방법 및 세포 표면 항원보호를 위한 이의 적용 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0297958A1 (ko) |
| JP (1) | JPS6426520A (ko) |
| KR (1) | KR890000109A (ko) |
| DK (1) | DK351588A (ko) |
| FR (1) | FR2617185B1 (ko) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100297462B1 (ko) * | 1999-05-17 | 2001-10-29 | 윤지현 | 생장호르몬 도포제의 도포방법 및 그 도포관 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0356258A3 (en) * | 1988-08-26 | 1990-06-06 | Cryopharm Corporation | Processes for the lyophilization of red blood cells, together with media for lyophilization |
| US6071745A (en) | 1997-06-27 | 2000-06-06 | Bio-Rad Laboratories | Method and formulation for lyophilizing cultured human cells to preserve RNA and DNA contained in cells for use in molecular biology experiments |
| US11584924B2 (en) | 2016-08-24 | 2023-02-21 | Infusion Tech | Method for concentrating microorganism or extracting nucleic acid using DTBP |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2551208C3 (de) * | 1975-11-14 | 1981-05-27 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung einer stabilen Erythrozyten-Präparation |
| US4675185A (en) * | 1985-12-06 | 1987-06-23 | Baxter Travenol Laboratories, Inc. | Solution for stabilizing red blood cells during storage |
-
1987
- 1987-06-25 FR FR8708964A patent/FR2617185B1/fr not_active Expired - Fee Related
-
1988
- 1988-06-24 EP EP88401608A patent/EP0297958A1/fr not_active Withdrawn
- 1988-06-24 JP JP63155068A patent/JPS6426520A/ja active Pending
- 1988-06-24 DK DK351588A patent/DK351588A/da not_active Application Discontinuation
- 1988-06-25 KR KR1019880007700A patent/KR890000109A/ko not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100297462B1 (ko) * | 1999-05-17 | 2001-10-29 | 윤지현 | 생장호르몬 도포제의 도포방법 및 그 도포관 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6426520A (en) | 1989-01-27 |
| FR2617185B1 (fr) | 1990-03-09 |
| DK351588A (da) | 1988-12-26 |
| DK351588D0 (da) | 1988-06-24 |
| EP0297958A1 (fr) | 1989-01-04 |
| FR2617185A1 (fr) | 1988-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7358039B2 (en) | Fixed-dried red blood cells | |
| Lovelock | The denaturation of lipid-protein complexes as a cause of damage by freezing | |
| DE68906458D1 (de) | Lyophilisation von erythrozyten und dafuer brauchbare mittel. | |
| ATE227071T1 (de) | Tiefkühlkonservierung von verschiedenen pflanzenzellen | |
| ATE120335T1 (de) | Verfahren zur lyophilisierung von zellen lyophilisierungsmedien und verfahren zur wiederherstellung von lyophilisierten zellen. | |
| FI884993A0 (fi) | Polypeptider. | |
| US4897353A (en) | Cryogenic protection of phosphofructokinase using amino acids and zinc ions | |
| KR900015715A (ko) | 약물을 함유하는 동결건조 제형물의 제조방법 | |
| US6358678B1 (en) | Applications of reversible crosslinking and co-treatment in stabilization and viral inactivations of erythrocytes | |
| HUP9902373A1 (hu) | Közeg biológiai anyagok tartósítására | |
| Feinstein et al. | The inhibition of human leucocyte elastase and chymotrypsin-like protease by elastatinal and chymostatin | |
| US4326025A (en) | Anti-hemolytic agent emulsions and the use thereof | |
| KR890000109A (ko) | 세포막의 안정화 방법 및 세포 표면 항원보호를 위한 이의 적용 | |
| SE8301795L (sv) | Plasminogenaktivatorkomplex | |
| IE34180B1 (en) | Preservation of organic material | |
| KR970058680A (ko) | 액상 진단약의 보존방법 | |
| DE69917681D1 (de) | Zusammensetzungen und verfahren zum konservieren von blutplättchen | |
| Armstrong et al. | Involvement of α2-macroglobulin and C-reactive protein in a complement-like hemolytic system in the arthropod, Limulus polyphemus | |
| US6436705B1 (en) | Shape stabilized erythrocytes | |
| Nelson | Ethanol protection against the catalase-depressing effect of 3-amino-1, 2, 4-triazole | |
| Ford et al. | The adverse effect of glycation of human serum albumin on its preservative activity in the freeze-drying and accelerated degradation of alkaline phosphatase | |
| RU2794766C1 (ru) | Композиционный биоматериал, обладающий гемостатической и регенеративной активностью (варианты) | |
| SU990228A1 (ru) | Способ консервировани клеток крови | |
| ATE98443T1 (de) | Steuerung der biologischen kennzeichen eines materials. | |
| Rho | Biochemical and Immunological Characterization of the DNA Polymerase and RNase H in Feline Leukemia Virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |